Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Overview

The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).

Full Title of Study: “A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 2012

Interventions

  • Drug: Levomilnacipran ER
    • Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
  • Drug: Paroxetine, Sertraline, Citalopram or Fluoxetine.
    • Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
  • Drug: Placebo
    • Matching placebo capsules, oral administration, once daily dosing

Arms, Groups and Cohorts

  • Experimental: 1
    • 40 -120 mg/day Levomilnacipran ER capsules, oral administration
  • Active Comparator: 2
    • Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) – Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
  • Placebo Comparator: 3
    • Matching placebo capsules, oral administration

Clinical Trial Outcome Measures

Primary Measures

  • Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
    • Time Frame: From Baseline to Week 8
    • The CGI-S is a clinician-rated scale that rates the severity of the patient’s current state of fatigue based on the Investigator’s clinical opinion with regard to the patient population with Major Depressive Disorder (MDD). Patient were rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating that the patient was among the most extremely fatigued
  • Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
    • Time Frame: From Baseline to Week 8
    • The PGI-S is a clinician-rated scale that rates was used to rate the severity of the patient’s current state of overall fatigue. Patients were rated on a scale from 1 to 7, with 1 indicating no symptoms of fatigue and 7 indicating extreme fatigue.

Secondary Measures

  • Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
    • Time Frame: From Baseline to Week 8
    • The Cognitive and Physical Functioning Questionnaire is a patient-rated, 7-item scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The CPFQ is sensitive to change with treatment and displays convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy, and neuropsychological functioning. Patients are rated on a scale from 1 to 6 for seven common complaints of depressed patients reporting fatigue or cognitive/executive problems-with 1 indicating greater than normal functioning, 2 indicating normal functioning, and 3 to 6 indicating degrees of impaired functioning. The CPFQ ranges from the best possible score of 7 (greater than normal functioning) to the worst possible score of 42 (totally absent).

Participating in This Clinical Trial

Inclusion Criteria

  • Men and women, 18-65 years old – Currently meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder – The patient's current depressive episode must be at least 4 weeks in duration Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women of child-bearing potential who are not practicing a reliable method of birth control – Patients with a history of meeting DSM-IV-TR criteria for: 1. any manic or hypomanic episode; 2. schizophrenia or any other psychotic disorder; 3. obsessive-compulsive disorder. – Patients who are considered a suicide risk

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Forest Laboratories
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Carl Gommoll, MS, Study Director, Forest Laboratories

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.